Information Provided By:
Fly News Breaks for January 22, 2018
ARCT
Jan 22, 2018 | 09:08 EDT
Chardan analyst Keay Nakae started Arcturus Therapeutics with a Buy rating and $12 price target, as he believes the company, formed by a merger with the former Alcobra, has the potential to become a significant competitor in the emerging fields of small-interfering RNA and messenger RNA. Arcturus' development pipeline currently has nine active programs and future progress updates from these programs could serve as potential positive catalysts, Nakae said.
News For ARCT From the Last 2 Days
There are no results for your query ARCT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.